Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:IKT NASDAQ:IZTC NASDAQ:LJPC NYSE:PLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$1.62$1.66$1.15▼$4.20$120.72M0.89180,332 shs51,702 shsIZTCInvizyne Technologies$13.50+1.5%$11.36$8.50▼$23.00$84.40MN/A37,647 shs4,226 shsLJPCLa Jolla Pharmaceutical$5.73$3.07▼$6.24$155.11M2.39158,476 shs66,708 shsPLXProtalix BioTherapeutics$2.50-3.8%$1.74$0.99▼$3.10$199.33M-0.13832,865 shs1.69 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics-2.41%+5.88%-2.99%-19.40%+28.57%IZTCInvizyne Technologies0.00%-14.08%+11.20%+30.60%+1,329,999,900.00%LJPCLa Jolla Pharmaceutical0.00%0.00%0.00%0.00%0.00%PLXProtalix BioTherapeutics+7.00%+20.37%+68.83%+75.68%+140.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$1.62$1.66$1.15▼$4.20$120.72M0.89180,332 shs51,702 shsIZTCInvizyne Technologies$13.50+1.5%$11.36$8.50▼$23.00$84.40MN/A37,647 shs4,226 shsLJPCLa Jolla Pharmaceutical$5.73$3.07▼$6.24$155.11M2.39158,476 shs66,708 shsPLXProtalix BioTherapeutics$2.50-3.8%$1.74$0.99▼$3.10$199.33M-0.13832,865 shs1.69 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics-2.41%+5.88%-2.99%-19.40%+28.57%IZTCInvizyne Technologies0.00%-14.08%+11.20%+30.60%+1,329,999,900.00%LJPCLa Jolla Pharmaceutical0.00%0.00%0.00%0.00%0.00%PLXProtalix BioTherapeutics+7.00%+20.37%+68.83%+75.68%+140.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIKTInhibikase Therapeutics 2.50Moderate Buy$6.50298.77% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/ALJPCLa Jolla Pharmaceutical 0.00N/AN/AN/APLXProtalix BioTherapeutics 3.00Buy$15.00501.20% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/ALJPCLa Jolla Pharmaceutical$75.72M0.00N/A7.95($2.94) per share0.00PLXProtalix BioTherapeutics$61.95M3.21$0.14 per share17.80$0.47 per share5.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/AIZTCInvizyne TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/ALJPCLa Jolla Pharmaceutical$19.66M$0.1251.840.00N/A8.54%-5.46%4.00%N/APLXProtalix BioTherapeutics$8.31M$0.07N/A8.05N/A-21.03%-30.89%-11.74%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/ALJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIKTInhibikase TherapeuticsN/A0.850.85IZTCInvizyne TechnologiesN/AN/AN/ALJPCLa Jolla PharmaceuticalN/A4.023.52PLXProtalix BioTherapeuticsN/A1.981.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIKTInhibikase Therapeutics3.81%IZTCInvizyne TechnologiesN/ALJPCLa Jolla Pharmaceutical97.06%PLXProtalix BioTherapeutics16.53%Insider OwnershipCompanyInsider OwnershipIKTInhibikase Therapeutics7.30%IZTCInvizyne TechnologiesN/ALJPCLa Jolla Pharmaceutical36.30%PLXProtalix BioTherapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIKTInhibikase Therapeutics674.52 million66.18 millionNot OptionableIZTCInvizyne Technologies296.25 millionN/AN/ALJPCLa Jolla Pharmaceutical6124.94 million15.89 millionOptionablePLXProtalix BioTherapeutics20079.73 million69.00 millionOptionableLJPC, PLX, IKT, and IZTC HeadlinesRecent News About These CompaniesProtalix BioTherapeutics, Inc. (PLX) Gains Investor Confidence With Major Stake IncreaseSeptember 29, 2025 | msn.comReviewing Protalix BioTherapeutics (NYSE:PLX) & Big Cypress Acquisition (OTCMKTS:BCYP)September 28, 2025 | americanbankingnews.comProtalix BioTherapeutics, Inc. $PLX Shares Purchased by Goldman Sachs Group Inc.September 24, 2025 | marketbeat.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics to Present at Investor Summit VirtualSeptember 11, 2025 | finanznachrichten.deProtalix BioTherapeutics to Present at Investor Summit VirtualSeptember 11, 2025 | accessnewswire.comAProtalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio RampAugust 25, 2025 | seekingalpha.comProtalix Amends Market Offering Agreement with H.C. WainwrightAugust 22, 2025 | msn.comPLX: New CFO to Take the ReinsAugust 16, 2025 | finance.yahoo.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | insidermonkey.comProtalix BioTherapeutics Reports Strong Q2 2025 ResultsAugust 15, 2025 | msn.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business ResultsAugust 14, 2025 | finanznachrichten.deProtalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comProtalix BioTherapeutics lifts revenue on strong Elfabrio demandAugust 14, 2025 | proactiveinvestors.comProtalix BioTherapeutics Reports Second Quarter 2025 Financial and Business ResultsAugust 14, 2025 | prnewswire.comProtalix BioTherapeutics, Inc. (NYSE:PLX) Director Aharon Schwartz Buys 129,000 SharesAugust 13, 2025 | insidertrades.comProtalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025August 7, 2025 | prnewswire.comProtalix Lawsuit Dismissed After Bylaws AmendmentAugust 1, 2025 | tipranks.comProtalix BioTherapeutics Names Gilad Mamlok Chief Financial OfficerJuly 21, 2025 | marketwatch.comProtalix BioTherapeutics Names SVP and CFOJuly 21, 2025 | contractpharma.comCProtalix Biotherapeutics Inc.: Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial OfficerJuly 21, 2025 | finanznachrichten.deProtalix BioTherapeutics welcomes new finance chiefJuly 21, 2025 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 20253 Hot Tech Stocks With Bullish Charts and Ample UpsideBy Thomas Hughes | September 15, 2025After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught?By Leo Miller | October 3, 2025LJPC, PLX, IKT, and IZTC Company DescriptionsInhibikase Therapeutics NYSE:IKT$1.62 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.62 0.00 (0.00%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Invizyne Technologies NASDAQ:IZTC$13.50 +0.20 (+1.50%) As of 10/6/2025Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.La Jolla Pharmaceutical NASDAQ:LJPCLa Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.Protalix BioTherapeutics NYSE:PLX$2.50 -0.10 (-3.85%) Closing price 04:00 PM EasternExtended Trading$2.56 +0.06 (+2.60%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Dividend Aristocrats to Buy Before Year’s End Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? TrumpRx Brings Pfizer Into the Green—Is It a Buy? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
